3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 3
2
Phase NA
1
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
51
fludarabine
38
Injections
32
Gemcitabine
25
Paclitaxel
24
Cisplatin
22
Radiotherapy
19
toripalimab
18
pembrolizumab
18
Carboplatin
17
Capecitabine
17
Fluorouracil
15
Oxaliplatin
14
Nivolumab
14
Docetaxel
12
camrelizumab
11
apatinib
11
Temozolomide
11
Immunotherapy, Adoptive
11
Cetuximab
11
Bevacizumab
10
Irinotecan
9
Drug Therapy
9
sintilimab
8
Etoposide
8
aldesleukin
7
Taxes
7
Rituximab
7
Radiosurgery
7
Peripheral Blood Stem Cell Transplantation
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Unknown
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled